The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials
Authors:
- David R. CornblathDCDavid R. Cornblath
- E. Jay BienenEBE. Jay Bienen
- Andrew R. BlightABAndrew R. Blight
- 1 May 2012
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 34 (5) , 1056-1069
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAnnals of Neurology, 2010
- Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialThe Lancet, 2009
- Dose comparison trial of sustained-release fampridine in multiple sclerosisNeurology, 2008
- Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging studyMultiple Sclerosis Journal, 2007
- Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatmentPharmacology & Therapeutics, 2006
- Molecular Diversity of K+ ChannelsAnnals of the New York Academy of Sciences, 1999
- Characterization of six voltage-gated K+ currents in adult rat sensory neuronsJournal of Neurophysiology, 1996
- Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injuryBrain Research Bulletin, 1989
- 4-aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerveBrain Research, 1985
- Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibresNature, 1980